Tumor-agnostic drug development Journal Article
| Authors: | Offin, M.; Liu, D.; Drilon, A. |
| Article Title: | Tumor-agnostic drug development |
| Abstract: | Therapies designed to target cancers that harbor specific molecular signatures have reshaped the landscape of oncologic drug development, and advances in next generation sequencing have led to an increase in the identification of these alterations across tumor types. Tumor-agnostic trial designs, such as the "basket trial," have been developed as an approach to study the efficacy of these treatments and increase patient access, especially for patients whose tumors carry these alterations infrequently. We review key aspects of these genomically enriched trial strategies and their impact on drug development and approval. |
| Keywords: | signal transduction; genetics; mutation; antineoplastic agents; clinical trials as topic; antineoplastic agent; neoplasm; neoplasms; metabolism; drug effect; drug discovery; drug development; tumor marker; gene expression regulation; gene expression regulation, neoplastic; clinical trial (topic); procedures; humans; human; biomarkers, tumor |
| Journal Title: | American Society of Clinical Oncology Educational Book |
| Volume: | 38 |
| ISSN: | 1548-8756 |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-23 |
| Start Page: | 184 |
| End Page: | 187 |
| Language: | English |
| DOI: | 10.1200/edbk_200831 |
| PROVIDER: | scopus |
| PUBMED: | 30231313 |
| PMCID: | PMC7506519 |
| DOI/URL: | |
| Notes: | Am Soc Clin Oncol Educ Book -- Export Date: 2 January 2019 -- Article -- Source: Scopus C2 - 30231313 |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work